|
1
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Uhlenhopp DJ, Then EO, Sunkara T and
Gaduputi V: Epidemiology of esophageal cancer: Update in global
trends, etiology and risk factors. Clin J Gastroenterol.
13:1010–1021. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang J, Zhao X, Wang Y, Liu T, Zhong C,
Lao Y, Zhang S, Liao H, Bai F, Lin D and Wu C: Genomic alterations
driving precancerous to cancerous lesions in esophageal cancer
development. Cancer Cell. 41:2038–2050.e5. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu WJ, Zhao Y, Chen X, Miao ML and Zhang
RQ: Epigenetic modifications in esophageal cancer: An evolving
biomarker. Front Genet. 13:10874792023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang L, Wang Y, Gao J, Zhou X, Huang M,
Wang X and He Z: Non-coding RNA: A promising diagnostic biomarker
and therapeutic target for esophageal squamous cell carcinoma
(review). Oncol Lett. 27:2552024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karakas D and Ozpolat B: The role of
LncRNAs in translation. Noncoding RNA. 7:162021.PubMed/NCBI
|
|
7
|
Herman AB, Tsitsipatis D and Gorospe M:
Integrated lncRNA function upon genomic and epigenomic regulation.
Mol Cell. 82:2252–2266. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ferrer J and Dimitrova N: Transcription
regulation by long non-coding RNAs: Mechanisms and disease
relevance. Nat Rev Mol Cell Biol. 25:396–415. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Piao HY, Guo S, Jin H, Wang Y and Zhang J:
LINC00184 involved in the regulatory network of ANGPT2 via ceRNA
mediated miR-145 inhibition in gastric cancer. J Cancer.
12:2336–2350. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yao Y, Zhang T, Qi L, Zhou C, Wei J, Feng
F, Liu R and Sun C: Integrated analysis of co-expression and ceRNA
network identifies five lncRNAs as prognostic markers for breast
cancer. J Cell Mol Med. 23:8410–8419. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weisenberger DJ, Lakshminarasimhan R and
Liang G: The role of DNA methylation and DNA methyltransferases in
cancer. Adv Exp Med Biol. 1389:317–348. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao N, Lai C, Wang Y, Dai S and Gu H:
Understanding the role of DNA methylation in colorectal cancer:
Mechanisms, detection, and clinical significance. Biochim Biophys
Acta Rev Cancer. 1879:1890962024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Z, Li B, Yu H, Wang P, Wang W, Hou P,
Li M, Chu S, Zheng J, Mao L and Bai J: DNMT1-mediated epigenetic
silencing of TRAF6 promotes prostate cancer tumorigenesis and
metastasis by enhancing EZH2 stability. Oncogene. 41:3991–4002.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li A, Omura N, Hong SM and Goggins M:
Pancreatic cancer DNMT1 expression and sensitivity to DNMT1
inhibitors. Cancer Biol Ther. 9:321–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Etoh T, Kanai Y, Ushijima S, Nakagawa T,
Nakanishi Y, Sasako M, Kitano S and Hirohashi S: Increased DNA
methyltransferase 1 (DNMT1) protein expression correlates
significantly with poorer tumor differentiation and frequent DNA
hypermethylation of multiple CpG islands in gastric cancers. Am J
Pathol. 164:689–699. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee KW, Lim S and Kim KD: The function of
N-Myc downstream-regulated gene 2 (NDRG2) as a negative regulator
in tumor cell metastasis. Int J Mol Sci. 23:93652022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li SJ, Wang WY, Li B, Chen B, Zhang B,
Wang X, Chen CS, Zhao QC, Shi H and Yao L: Expression of NDRG2 in
human lung cancer and its correlation with prognosis. Med Oncol.
30:4212013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li
X and Yao LB: NDRG2 expression and mutation in human liver and
pancreatic cancers. World J Gastroenterol. 10:3518–3521. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng RB, Zhou QZ, Cheng R, Li P, Zhu ST,
Min L and Zhang ST: Expression and significance of N-myc downstream
regulated gene 2 in the process of esophageal squamous cell
carcinogenesis. Bioengineered. 13:3275–3283. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahn CH, Kim JH, Shim HW, Shin WJ, Cho YA
and Yoon HJ: Biological and prognostic significance of NDRG2
downregulation in oral squamous cell carcinoma. Oral Dis.
30:4287–4302. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Morishita K, Nakahata S and Ichikawa T:
Pathophysiological significance of N-myc downstream-regulated gene
2 in cancer development through protein phosphatase 2A
phosphorylation regulation. Cancer Sci. 112:22–30. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo Q, Du R, Liu W, Huang G, Dong Z and Li
X: PI3K/Akt/mTOR signaling pathway: Role in esophageal squamous
cell carcinoma, regulatory mechanisms and opportunities for
targeted therapy. Front Oncol. 12:8523832022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang W, Li H, Yu Q, Xiao W and Wang DO:
LncRNA-mediated DNA methylation: An emerging mechanism in cancer
and beyond. J Exp Clin Cancer Res. 41:1002022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han Y, You J, Han Y, Liu Y, Huang M, Lu X,
Chen J and Zheng Y: LINC00184 promotes ovarian cancer cells
proliferation and cisplatin resistance by elevating CNTN1
expression via sponging miR-1305. Onco Targets Ther. 14:2711–2726.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang W, Xin J, Lai J and Zhang W: LncRNA
LINC00184 promotes docetaxel resistance and immune escape via
miR-105-5p/PD-L1 axis in prostate cancer. Immunobiology.
227:1521632022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun HB, Zhang GC, Liu J and Nie CS: Long
noncoding RNA LINC00184 facilitates the proliferation, metastasis,
and adenine metabolism of cholangiocarcinoma via modulating
hsa-miR-23b-3p/ANXA2 axis. Environ Toxicol. 36:1576–1590. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang W, Li L and Zhao L: LINC00184 plays
an oncogenic role in non-small cell lung cancer via regulation of
the miR-524-5p/HMGB2 axis. J Cell Mol Med. 25:9927–9938. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao L, Zhang J and Liu X: NDRG2: A
Myc-repressed gene involved in cancer and cell stress. Acta Biochim
Biophys Sin (Shanghai). 40:625–635. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Feng L, Xie Y, Zhang H and Wu Y:
Down-regulation of NDRG2 gene expression in human colorectal cancer
involves promoter methylation and microRNA-650. Biochem Biophys Res
Commun. 406:534–538. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tantai J, Pan X and Hu D: RNF4-mediated
SUMOylation is essential for NDRG2 suppression of lung
adenocarcinoma. Oncotarget. 7:26837–26843. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma Z, Ma Y, Feng J, Xu Z, Cheng C, Qin J,
Li S, Jiang J and Kong R: NDRG2 acts as a negative regulator of the
progression of small-cell lung cancer through the modulation of the
PTEN-AKT-mTOR signalling cascade. Toxicol Appl Pharmacol.
485:1169152024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ,
Park IY, Sohn BH, Sohn HA, Lee HG, Lim JS, et al: Functional and
clinical evidence for NDRG2 as a candidate suppressor of liver
cancer metastasis. Cancer Res. 68:4210–4220. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng J, Liu Q, Li Y, Yang J, Ma J, Yu F,
Shi H, Ren Q, Zhang R, Zhang J, et al: NDRG2 expression regulates
CD24 and metastatic potential of breast cancer cells. Asian Pac J
Cancer Prev. 11:1817–1821. 2020.PubMed/NCBI
|
|
35
|
Liu B, Wang C, Chen P, Cheng B and Cheng
Y: RACKI induces chemotherapy resistance in esophageal carcinoma by
upregulating the PI3K/AKT pathway and Bcl-2 expression. Onco
Targets Ther. 11:211–220. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shi N, Yu H and Chen T: Inhibition of
esophageal cancer growth through the suppression of PI3K/AKT/mTOR
signaling pathway. Onco Targets Ther. 12:7637–7647. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sigalotti L, Altomonte M, Colizzi F, Degan
M, Rupolo M, Zagonel V, Pinto A, Gattei V and Maio M:
5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic
malignancies: A multimechanism therapeutic approach? Blood.
101:4644–4646. 2003. View Article : Google Scholar : PubMed/NCBI
|
